Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants

Pediatric Research

Volumn 82, Issue 5, 2017, Pages 872-880

  Brint, Monica E ^a   Hughes, Joshua M ^b   Shah, Aditya ^c   Miller, Chelsea R ^c   Harrison, Lisa G ^a   Meals, Elizabeth A ^a   Blanch, Jacqueline ^a   Thompson, Charlotte R ^c   Cormier, Stephania A ^a   DeVincenzo, John P ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; DYNAMICS; FEMALE; FOLLOW UP; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NOSE SMEAR; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REBOUND; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; KINETICS; LONGITUDINAL STUDY; NEWBORN; NOSE CAVITY; VIROLOGY;

VIRUS DNA;

DNA, VIRAL; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; INFANT; INFANT, NEWBORN; KINETICS; LONGITUDINAL STUDIES; MALE; NASAL CAVITY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL LOAD; VIRUS REPLICATION;

EID: 85031720410     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2017.173     Document Type: Article

References (20)

1. Simões EA, Devincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 2015;211(Suppl 1):S1-20.
2. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137:865-70.
3. Buckingham SC, Bush AJ, Devincenzo JP. Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J 2000;19:113-7.
4. Devincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005;191:1861-8.
5. Devincenzo JP, Wilkinson T, Vaishnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010;182:1305-14.
6. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 2011;204: 996-1002.
7. Hall CB, Douglas RG, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr 1976;89:11-5.
8. Ginocchio CC. Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens. Clin Infect Dis 2011;52 (Suppl 4): S312-25.
9. Bagga B, Cehelsky JE, Vaishnaw A, et al. Effect of preexisting serum and mucosal antibody on experimental respiratory syncytial virus (RSV) challenge and infection of adults. J Infect Dis 2015;212:1719-25.
10. Devincenzo JP, Mcclure MW, Symons JA, et al. Activity of oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med 2015;373:2048-58.
11. Perkins SM, Webb DL, Torrance SA, et al. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol 2005;43:2356-62.
12. Lagos R, Devincenzo JP, Muñoz A, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J 2009;28:835-7.
13. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008;82:2040-55.
14. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008;178:854-60.
15. Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther 2009;14:75-85.
16. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006;12:48-54.
17. Pickles RJ, Devincenzo JP. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis. J Pathol 2015;235:266-76.
18. Grad YH, Newman R, Zody M, et al. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol 2014;88:7286-93.
19. Kim-Hoehamer Y-I, Lau J, Murphy R, et al. Deep-sequencing of longitudinal samples from RSV-infected adults and infants reveals heterogeneous dynamics of within-host viral diversification. J Immunol 2016;196(Suppl 1):80.8
20. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med 2015;191:34-44.